Syncom Formulations (India) Limited (524470) Fair Value & Analysis
Healthcare · IN · Market cap ₹976M
Fair value as of: Jul 4, 2026
From 26 valuation models · updated today
Share price −3.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹10.30 – ₹19.42 · fair‑value band ₹5.06 – ₹13.46 · the ₹14.23 price screens above the ₹10.20 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Syncom Formulations (India) Limited (524470) currently trades at ₹14.23, while our model-based Fair Value estimate is ₹10.20 — implying the stock looks roughly 28.3% overvalued today. We read business quality at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Syncom Formulations (India) Limited generated revenue of ₹1.8B at a net margin of 7.9%. Revenue declined 45.7% year over year. The stock trades on a trailing P/E of 10.2. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Syncom Formulations (India) Limited, a pharmaceutical company, discovers, develops, manufactures, and markets a range of healthcare products in India. The company offers approximately 300 pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoules injections, dry vial injections, dry syrups, ointments, inhalers, and herbals. Its products comprise generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also offers histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Syncom Formulations (India) Limited reported revenue of ₹4.7B in FY2025 versus ₹2.4B in FY2021, a compound +17.4%/yr. Reported net income was ₹494M in FY2025, compounding +14.1%/yr from FY2021.
Is 524470 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Makers Laboratories Limited 506919 | ₹151.45 | ₹105.20 | -31% |
| Syschem (India) Limited 531173 | ₹40.64 | ₹6.95 | -83% |
| Unjha Formulations Limited 531762 | ₹18.55 | ₹34.60 | +87% |
| Colinz Laboratories Limited 531210 | ₹77.55 | ₹14.60 | -81% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| UnitedHealth Group UNH | 7,169 MXN | 5,226 MXN | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Syncom Formulations (India) Limited (524470) undervalued?
What is the fair value of 524470?
What is the quality score of 524470?
What is the revenue of Syncom Formulations (India) Limited (524470)?
What is the net profit margin of 524470?
Does Syncom Formulations (India) Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.